ArticleOncoTargets and therapy2012
Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.
Article in OncoTargets and therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Clinical Outcomes and Effectiveness of CRLX101 for Solid Tumors: A Systematic Review and Meta-analysis.Current medicinal chemistry · 2025Pooled it
- Correlation Between Early Time-to-Event Outcomes and Overall Survival in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Receiving Definitive Chemoradiation Therapy: Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Model-based meta-analysis of progression-free survival in non-Hodgkin lymphoma patients.Medicine · 2017Pooled it
- Pooled it
- Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer.Journal of gynecologic oncology · 2019Article
- Endpoint surrogacy in oncological randomized controlled trials with immunotherapies: a systematic review of trial-level and arm-level meta-analyses.Annals of translational medicine · 2019Review
- A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses.JNCI cancer spectrum · 2019Review
- Oncologic orphan drugs approved in the EU - do clinical trial data correspond with real-world effectiveness?Orphanet journal of rare diseases · 2018Article
- Kernel machine score test for pathway analysis in the presence of semi-competing risks.Statistical methods in medical research · 2018Article
- Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Article
- RECIST - learning from the past to build the future.Nature reviews. Clinical oncology · 2017Review
- Endpoints and cutpoints in head and neck oncology trials: methodical background, challenges, current practice and perspectives.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2016Review
- Evaluation of a cloud-based local-read paradigm for imaging evaluations in oncology clinical trials for lung cancer.Acta radiologica open · 2015Article
- Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis.Current oncology (Toronto, Ont.) · 2015Article
- Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?BioMed research international · 2015Review
- Effect of tyrosine kinase inhibitors on wound healing and tissue repair: implications for surgery in cancer patients.Drug safety · 2014Review
- Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer.OncoTargets and therapy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overall survival (OS) is the gold standard in measuring the treatment effect of new drug therapies for cancer. However, practical factors may preclude the collection of unconfounded OS data, and surrogate endpoints are often used instead. Meta-analyses have been widely used for the validation of surrogate endpoints, specifically in oncology. This research reviewed published meta-analyses on the types of surrogate measures used in oncology studies and examined the extent of correlation between surrogate endpoints and OS for different cancer types. A search was conducted in October 2010 to compile available published evidence in the English language for the validation of disease progression-related endpoints as surrogates of OS, based on meta-analyses. We summarize published meta-analyses that quantified the correlation between progression-based endpoints and OS for multiple advanced solid-tumor types. We also discuss issues that affect the interpretation of these findings. Progression-free survival is the most commonly used surrogate measure in studies of advanced solid tumors, and correlation with OS is reported for a limited number of cancer types. Given the increased use of crossover in trials and the availability of second-/third-line treatment options available to patients after progression, it will become increasingly more difficult to establish correlation between effects on progression-free survival and OS in additional tumor types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.